Hepatitis C and injecting drug use: impact, costs and policy options

Series type: Monographs


Hepatitis C infections occurring in recent years in the European Union may cost countries billions of euros in future healthcare, according to research published in this monograph. A conglomeration of state-of-the-art research on hepatitis C, drug use and public health methods, this publication presents analyses on the impact and costs of the disease among injecting drug users, as a basis for sound policy-making. Other issues addressed include: quality of life; treatment, surveillance and prevention; and the cost-effectiveness of measures such as needle-exchange programmes and substitution therapy. Hepatitis C affects an estimated 170 million people worldwide and at least a million, but possibly several million, people in Western Europe who are at risk of developing liver cirrhosis or liver cancer. It is a highly infectious and potentially fatal blood-borne disease that attacks the liver and for which there is as yet no vaccine.

Download as PDF

Table of contents

  • Part I: Natural history, treatment, quality of life, epidemiology and prevention
  • Part II: Models of hepatitis C in injecting drug users
  • Part III: Healthcare costs of drug-related hepatitis C infection
  • Part IV: Wider costs of drug use
  • Part V: Cost-effectiveness of needle and syringe programmes and methadone maintenance
Catalog Number: 

Order this publication from EU Publications >>